Factors influencing the efficacy of nebulized colistimethate sodium in the treatment of severe lung infection caused by carbapenem-resistant gram-negative bacteria - PubMed
3 hours ago
- #Carbapenem-resistant gram-negative bacteria
- #Severe pneumonia
- #Nebulized colistimethate sodium
- Nebulized colistimethate sodium (CMS) shows clinical benefits for treating severe pneumonia caused by carbapenem-resistant gram-negative bacteria (CR-GNB).
- In a study of 314 patients, treatment with nebulized CMS achieved 76.1% microbiological efficacy and a 79.3% overall clinical response rate, with a 20.1% mortality rate.
- Factors associated with lower bacterial clearance include older age, history of stroke, and combination treatment with tigecycline.
- Prior use of moxifloxacin and tigecycline treatment were linked to a lower clinical response to nebulized CMS.
- Tigecycline treatment was independently associated with a higher risk of death in patients receiving nebulized CMS therapy.
- The findings help identify factors that may optimize the clinical use of nebulized CMS for severe CR-GNB infections.